Nimorazole (INN) is a nitroimidazole anti-infective.[1] It is also being investigated for the treatment of head and neck cancer.[2][3]

Nimorazole
Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
  • 4-[2-(5-nitro-1H-imidazol-1-yl)ethyl]morpholine
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
ECHA InfoCard100.026.723 Edit this at Wikidata
Chemical and physical data
FormulaC9H14N4O3
Molar mass226.236 g·mol−1
3D model (JSmol)
  • C1COCCN1CCN2C=NC=C2[N+](=O)[O-]
  • InChI=1S/C9H14N4O3/c14-13(15)9-7-10-8-12(9)2-1-11-3-5-16-6-4-11/h7-8H,1-6H2
  • Key:MDJFHRLTPRPZLY-UHFFFAOYSA-N
  (verify)

References

edit
  1. ^ Roy RB, Laird SM, Heasman L (August 1975). "Treatment of trichomoniasis in the female. A comparison of metronidazole and nimorazole". The British Journal of Venereal Diseases. 51 (4): 281–4. doi:10.1136/sti.51.4.281. PMC 1046566. PMID 1098732.
  2. ^ Henk JM, Bishop K, Shepherd SF (January 2003). "Treatment of head and neck cancer with CHART and nimorazole: phase II study". Radiotherapy and Oncology. 66 (1): 65–70. doi:10.1016/S0167-8140(02)00284-0. PMID 12559522.
  3. ^ Clinical trial number NCT01507467 for "IAEA-HypoX. Accelerated Radiotherapy With or Without Nimorazole in Squamous Cell Carcinoma of the Head and Neck" at ClinicalTrials.gov